Related Experiment Videos
[Clinical evaluation of cefmenoxime in severe infections in leukemia and related disorders]
Abstract:
Ninety nine patients with leukemia and/or related disorders were treated with cefmenoxime (CMX). Among them, 77 patients had severe infections, while other 22 patients did not suffer from infection, but it was expected that they would fall into serious conditions if they were infected. Sixty of the 77 patients who had severe infection were used in the evaluation of effectiveness. The remaining 17 patients were not evaluated because they were subjected to combined treatments of CMX and other therapeutic agents such as other antibiotics, gamma-globulin or interferon. Excellent responses were found in 26 (43.3%) patients and good responses in 12 (20.0%) patients. In total, the rate of effectiveness was 63.3%. Nineteen of the 22 patients who were treated prophylactically with CMX were used in the evaluation of effectiveness, while 3 patients were excluded from the evaluation because peripheral neutrophils were counted to be more than 1,000/mm3 before CMX was administrated, although these 3 patients were used in the final evaluation to examine side effects. In the prophylactic treatment, the rate of effectiveness was 89.5%. The side effects were seen in 4 patients (4/82:4.9%). A different symptom was identified in each patient. These symptoms were skin rash, mild nausea, mild diarrhea and slight elevation of serum bilirubin. Prompt improvements of these symptoms occurred as soon as CMX administration was stopped. These results show that CMX is a therapeutically effective and safe antibiotics for the treatment of severe infections or for the prophylaxis of infections in patients associated with leukemia and/or related disorders.
Insights
Cefmenoxime (CMX) effectively treated severe infections and prevented infections in leukemia patients. This antibiotic demonstrated a 63.3% effectiveness rate for treatment and 89.5% for prophylaxis, with minimal side effects.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacology
Context:
- Leukemia and related disorders compromise immune function, increasing susceptibility to severe infections.
- Patients with hematological malignancies often require antimicrobial therapy for both treatment and prevention of infections.
- Evaluating novel antibiotic efficacy in immunocompromised populations is crucial for clinical practice.
Purpose:
- To assess the therapeutic efficacy and safety of cefmenoxime (CMX) in patients with leukemia and/or related disorders.
- To determine the effectiveness of CMX in treating severe infections in this patient cohort.
- To evaluate the prophylactic use of CMX in preventing infections in at-risk leukemia patients.
Summary:
- A study involving 99 leukemia patients evaluated cefmenoxime (CMX) for treating severe infections and for prophylaxis.
- For therapeutic use, CMX showed a 63.3% effectiveness rate in 60 patients with severe infections.
- Prophylactic administration of CMX in 19 patients achieved an 89.5% effectiveness rate, with only 4.9% experiencing mild side effects.
Impact:
- Cefmenoxime (CMX) is demonstrated to be a safe and effective antibiotic option for managing infections in leukemia patients.
- The findings support the use of CMX for both treating existing severe infections and preventing new infections in this vulnerable group.
- This research contributes to evidence-based antimicrobial strategies in hematology-oncology settings.